Cargando…

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

Virus-based vaccines and appropriate costimulation potently enhance antigen-specific T cell immunity against cancer. Here we report the use of recombinant modified vaccinia virus Ankara (rMVA) encoding costimulatory CD40L against solid tumors. Therapeutic treatment with rMVA-CD40L-expressing tumor-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medina-Echeverz, José, Hinterberger, Maria, Testori, Marco, Geiger, Marlene, Giessel, Raphael, Bathke, Barbara, Kassub, Ronny, Gräbnitz, Fabienne, Fiore, Giovanna, Wennier, Sonia T., Chaplin, Paul, Suter, Mark, Hochrein, Hubertus, Lauterbach, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834557/ https://www.ncbi.nlm.nih.gov/pubmed/31695037 http://dx.doi.org/10.1038/s41467-019-12998-6

Ejemplares similares

NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin
por: Sanos, Stephanie L., et al.
Publicado: (2018)

Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity
por: Lauterbach, Henning, et al.
Publicado: (2013)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

CD70 encoded by modified vaccinia virus Ankara enhances CD8 T‐cell‐dependent protective immunity in MHC class II‐deficient mice
por: Bathke, Barbara, et al.
Publicado: (2018)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
por: Hinterberger, Maria, et al.
Publicado: (2023)

A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
por: Endt, Kathrin, et al.
Publicado: (2022)

Mouse CD8α(+) DCs and human BDCA3(+) DCs are major producers of IFN-λ in response to poly IC
por: Lauterbach, Henning, et al.
Publicado: (2010)

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2022)

MyD88-dependent pro-interleukin-1β induction in dendritic cells exposed to food-grade synthetic amorphous silica
por: Winkler, Hans Christian, et al.
Publicado: (2017)

Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations
por: Palgen, Jean-Louis, et al.
Publicado: (2020)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

The 90 MVA transformer
Publicado: (1974)

Bacteria evade immune recognition via TLR13 and binding of their 23S rRNA by MLS antibiotics by the same mechanisms
por: Hochrein, Hubertus, et al.
Publicado: (2013)

Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2023)

An MVA Approach to Missing $E_T$
por: Herwig, Theodor Christian
Publicado: (2013)

Ciliopathy in PCS (MVA) syndrome
por: Miyamoto, Tatsuo, et al.
Publicado: (2015)

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015)

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency
por: Weidenthaler, Heinz, et al.
Publicado: (2022)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015)

Mechanism of pyocyanin abolishment caused by mvaT mvaU double knockout in Pseudomonas aeruginosa PAO1
por: Dong, Limin, et al.
Publicado: (2019)

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE(®) against aerosolized rabbitpox virus in a rabbit model()
por: Garza, Nicole L., et al.
Publicado: (2009)

The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses
por: Tao, Sha, et al.
Publicado: (2019)

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses
por: Wennier, Sonia T., et al.
Publicado: (2013)

Installing a 220 MVA power transformer
por: Ordan, Julien Marius, et al.
Publicado: (2018)

Installation of a 70 MVA Power Transformer
por: Balle, Christoph
Publicado: (2013)

LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
por: Maclennan, Jane, et al.
Publicado: (2019)

Agonistic CD40 antibody induces immune-mediated liver damage and modulates tumor-induced myeloid suppressive cells
por: Medina-Echeverz, Jose, et al.
Publicado: (2014)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
por: Delaloye, Julie, et al.
Publicado: (2009)

The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
por: Jenkins, Victoria A., et al.
Publicado: (2023)

Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
Publicado: (2022)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Surgery 4.0: the natural culmination of the industrial revolution?
por: Feußner, Hubertus, et al.
Publicado: (2017)

Non‐neutralizing antibodies protect against chronic LCMV infection by promoting infection of inflammatory monocytes in mice
por: Stoycheva, Diana, et al.
Publicado: (2021)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
por: Rollier, Christine S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9shn77g44d5062o7j6bl9h36oe